What Abera Bioscience does

Abera Bioscience AB is a Swedish biotechnology company founded in 2012 as a spin-out from Stockholm University and Vrije Universiteit Amsterdam. It is headquartered in Uppsala at Virdings allé 32 and listed on Spotlight Stock Market under ticker ABERA since February 2021. The company develops next-generation mucosal (intranasal) vaccines using its proprietary BERA platform, which is based on Outer Membrane Vesicles (OMVs) carrying disease-specific antigens coupled via a modular plug-and-display system. The lead clinical candidate, Ab-01.12, is a first-in-class serotype-independent pneumococcal vaccine targeting all ~100 variants of Streptococcus pneumoniae; it completed GMP production in June 2026 and is preparing a Clinical Trial Application for a first-in-human study at Radboud UMC in the Netherlands. Earlier-stage programs cover influenza, COVID-19, tuberculosis, and chlamydia, with influenza supported by CEPI funding.

The business model is asset-light and licensing-oriented rather than product-sales-driven. Abera develops vaccine candidates through late preclinical or early clinical phases and then out-licenses them to larger pharmaceutical partners; it also licenses the BERA platform for indications outside its internal focus. Revenue mechanics consist of upfront payments, milestones, and royalties - none of which have yet materialized. Capitalization today combines non-dilutive grants (CEPI, Vinnova, UK Vaccine Network, BactiVac) with equity. A directed share issue in January 2026 raised approximately 10 mSEK from professional investor Göran Ofsén, following a heavily oversubscribed 2021 IPO that raised approximately 24.1 MSEK. The company reported 0 kSEK in net sales in Q1 2026, with 3,553 kSEK in other operating income (grant-funded) and a Q1 result after financial items of -5,796 kSEK; equity ratio stood at 76%. Manufacturing economics are positioned at an estimated ~5% of the cost of traditional pneumococcal conjugate vaccines, leveraging egg-free controlled liquid fermentation, and the company has validated both liquid nasal spray and dry powder (via Orexo's AmorphOX technology) formulations.

Name

Abera Bioscience

Legal name

Abera Bioscience AB

Website

https://aberabio.com

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Short description

Abera Bioscience is a Swedish preclinical-stage biotech that develops mucosal (intranasal) vaccines using its proprietary BERA Outer Membrane Vesicle platform, targeting pneumococcal disease, influenza, and other infectious diseases, and plans to out-license candidates and the platform to larger pharmaceutical partners.

Ownership category

akta.pro rank

Product category

Mucosal Vaccines / Biotechnology R&D

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

akta.pro secondary industries

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), Pandemic Preparedness & Rapid-Response Vaccines (HLAIAEAF), Seasonal & Endemic Vaccines (e.g., Influenza) (HLAIAEAD), Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)

Keywords

• Mucosal vaccine platform
• Outer membrane vesicle technology
• Nasal spray vaccines
• Serotype-independent pneumococcal vaccine
• Pandemic preparedness vaccines

Headquarters

HQ city

Uppsala

HQ country

Sweden

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Out-licensing of Vaccine Candidates: Abera develops vaccine candidates based on its BERA platform through late preclinical or early clinical phases, then licenses them to larger pharmaceutical companies. Market potential for the pneumococcal vaccine Ab-01.12 is estimated by the board at approximately 6,000 MUSD annually. The platform's market potential is estimated at approximately 250 MEUR based on comparable licensing deals.
2. Platform Licensing (Out-licensing): Abera licenses the use of its BERA platform within indications it does not focus on. Potential for revenue in terms of royalties and upfront payments. The platform is described as applicable across many areas generating revenue streams.
3. Grants and Non-Dilutive Funding: Abera receives grants from CEPI (extended until December 2026), BactiVac (£70,000 for spray applicator studies), UK Vaccine Network, and Vinnova (1 million SEK). In 2024, over 35 MSEK was attracted in grants. Currently pre-revenue with net sales of 0 kSEK in Q1 2026.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Abera Bioscience develops a proprietary BERA Outer Membrane Vesicle (OMV) vaccine platform that allows modular, plug-and-display coupling of disease-specific antigens onto standardized bacterial vesicles. The company's lead product, the intranasal pneumococcal vaccine candidate Ab-01.12, targets all ~100 Streptococcus pneumoniae serotypes and is preparing for Phase 1 clinical trials; an intranasal influenza candidate and earlier-stage programs in COVID-19, tuberculosis, and chlamydia round out the pipeline. Abera monetizes by out-licensing candidates and the platform itself, and it has not yet commercialized any product.

Product overview

Abera Bioscience is a Swedish biotechnology company developing next-generation mucosal vaccines based on its proprietary BERA OMV vaccine platform. The portfolio consists of a lead clinical-stage product (Ab-01.12, a serotype-independent nasal pneumococcal vaccine entering Phase 1), an advanced preclinical intranasal influenza vaccine candidate, and earlier-stage programs in pandemic preparedness, COVID-19, tuberculosis, and chlamydia. The BERA platform uses a modular outer membrane vesicle (OMV) backbone with a plug-and-display antigen coupling system, enabling rapid vaccine design, needle-free intranasal delivery, and scalable microbial manufacturing. The platform supports both liquid nasal spray and dry powder formulations.

Differentiator

Problem solved

Functional benefit

Products and services

• BERA Vaccine Platform (OMV plug-and-display) Proprietary modular Outer Membrane Vesicle (OMV) vaccine platform with standardized vesicles acting as a natural adjuvant and display surface. Disease-specific antigens are covalently coupled in a plug-and-play manner, enabling rapid generation of new mucosal vaccine candidates when pathogen sequences become available. The platform supports scalable manufacturing via controlled microbial fermentation without eggs and needle-free intranasal delivery as nasal spray or dry powder. Offered to pharmaceutical and biotech partners via licensing for indications outside Abera's internal focus.
• Ab-01.12 (Serotype-independent nasal pneumococcal vaccine candidate) First-in-class intranasal vaccine candidate targeting all ~100 Streptococcus pneumoniae serotypes using conserved protein antigens (>99% conserved) displayed on OMVs via the BERA platform. Induces both mucosal IgA in nose and lungs and systemic IgG, targeting initial colonization to block transmission. Demonstrated 1,000x better protection against colonization versus Prevnar 13 in mouse studies. GMP production of clinical trial material completed in June 2026 with Clinical Trial Application submission planned and first patient expected autumn 2026 at Radboud UMC, Netherlands. Designed to be out-licensed to a larger pharmaceutical partner after clinical proof-of-concept.
• Intranasal influenza vaccine candidate Influenza A vaccine candidate based on the BERA platform, coupling hemagglutinin (HA) antigens to OMVs via the plug-and-display system. In mouse studies, the high-dose group showed no detectable virus in nasal lavage or lung tissue three days post-infection with no clinical signs of disease, while controls had 67% mortality. Immune response was durable for at least 120 days. A free HA antigen without OMVs induced no measurable immune response, demonstrating the OMV platform's strong immunostimulatory effect. Validated in both liquid nasal spray and dry powder formulations (via Orexo AmorphOX technology) and supported by CEPI funding for pandemic preparedness.

Quantifiable outcome

• Ab-01.12 demonstrated 1000x better protection against pneumococcal colonization vs. Prevnar 13 in mouse studies
• +4 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Six partnerships are on record, tiered supporting and core.

• Artemis Bioservices (Delft, Netherlands)supportingStrategic or Co-development Partner · 23 June 2026Artemis Bioservices collaborated with Abera on preclinical studies of the intranasal influenza vaccine candidate. The study was conducted in part in collaboration with Artemis Bioservices and was funded with support from CEPI.
• Radboud UMCcoreStrategic or Co-development Partner · 8 June 2026Abera's clinical partner for the first-in-human study of Ab-01.12 pneumococcal vaccine candidate. The sequential dose-escalation study will evaluate safety, tolerability, and immunological markers in healthy subjects at Radboud UMC in Nijmegen, the Netherlands. Abera and Radboud UMC are prepared and ready to initiate the trial as soon as regulatory approval is obtained, with first patient expected in autumn 2026.
• Professor Marien de Jonge (Research Collaborator)supportingStrategic or Co-development Partner · 1 April 2026Professor Marien de Jonge played central and driving roles in the research collaboration that produced the npj Vaccines publication on the mechanism of action of Ab-01.12. Participated in panel discussions at international pneumococcal conferences, highlighting mucosal administration opportunities for future vaccine development.
• Orexo ABcoreStrategic or Co-development Partner · 17 December 2024Abera and Orexo entered a strategic collaboration in 2024 to develop and test Abera's influenza vaccine candidate in dry powder formulation using Orexo's AmorphOX technology. Preclinical study in rats (April 2025) confirmed both liquid nasal spray and dry powder formulations generated comparable high systemic antibody levels and strong local immune responses in nose and lungs. Powder formulations offer advantages in logistics, thermal stability, and potential self-administration during mass vaccination campaigns.
• Johns Hopkins School of MedicinesupportingStrategic or Co-development PartnerAbera partnered with Johns Hopkins School of Medicine during the COVID-19 pandemic to develop a COVID-19 vaccine candidate based on Abera's OMV platform. The collaboration produced excellent results demonstrating strong local and systemic protection in animal models.
• PricewaterhouseCoopers AB (PwC)supportingOthersPwC appointed as Abera's auditor at the 2025 Annual General Meeting, with Magnus Lagerberg as the principal auditor in charge.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Intravacc: Dutch-based vaccine R&D organization specializing in Outer Membrane Vesicle (OMV) vaccine platforms and delivery technologies. Most direct technical peer to Abera given both companies build on OMV-based vaccine approaches, though Intravacc focuses on broader infectious disease targets and has more advanced clinical programs.
• Vaxcyte: US-based clinical-stage biotech developing next-generation pneumococcal vaccines including VAX-24 (24-valent) and VAX-31 (31-valent) conjugates using a cell-free protein synthesis platform. Direct competitive peer to Ab-01.12 in the serotype-coverage-expansion pneumococcal vaccine space with more advanced clinical development.
• Affinivax: Biotech developing multiple antigen presenting system (MAPS) vaccines with lead candidate ASP3772, a 24-valent pneumococcal vaccine. Direct peer in next-generation pneumococcal vaccine development acquired/partnered with Astellas; represents competitive approach to broader serotype coverage.
• Altimmune: US clinical-stage biopharmaceutical company developing intranasal vaccines including T-COVID (intranasal COVID-19 vaccine) and NasoVAX (intranasal influenza). Direct peer in intranasal/mucosal vaccine delivery, sharing Abera's needle-free approach to inducing mucosal immunity.
• Vaxart: Clinical-stage biotech developing oral tablet vaccines that induce mucosal and systemic immunity, with candidates in COVID-19, norovirus, influenza, and HPV. Peer in needle-free mucosal vaccine administration, though uses oral rather than intranasal delivery; comparable business model as pre-revenue licensing-platform biotech.

Emerging players

• Inventprise: Seattle-based clinical-stage biotech developing next-generation pneumococcal vaccines with broader serotype coverage using novel conjugation chemistry. Emerging peer in the same serotype-coverage-expansion theme but with different underlying technology than OMV-based approaches.
• Meissa Vaccines: Clinical-stage biotech developing intranasal live-attenuated vaccines for RSV and other respiratory pathogens, including MV-012-968 for pediatric RSV. Emerging peer in intranasal respiratory vaccines targeting similar mucosal immunity thesis for pediatric and global health applications.

Broad incumbents

• Pfizer: Global pharmaceutical incumbent dominating the pneumococcal vaccine market with Prevnar 13 and Prevnar 20 generating multi-billion annual revenues. Broad incumbent whose commercial franchise represents the primary competitive threat and most likely large-pharma licensing partner for Abera's Ab-01.12.
• GSK: Global vaccine leader with extensive pneumococcal (Synflorix), meningitis (Bexsero OMV-based), and influenza portfolios. Broad incumbent with relevant OMV expertise (Bexsero) making it both a likely licensing partner and a competitive threat for Abera's mucosal platform programs.
• Sanofi Pasteur: Global vaccine division of Sanofi with broad respiratory and infectious disease portfolio including influenza vaccines (Fluzone, Flublok) and significant pandemic preparedness investment. Broad incumbent and potential large-pharma licensing partner for Abera's intranasal platform programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abera Bioscience